Sad But True is not only the title of a song by the famous metal band Metallica, but also a fitting description of the predicted disease burden of liver cancer 25 years from now. According to the Global Cancer Observatory, the number of global cases of liver cancer is expected to rise from 0.87 million in 2022 to over 1.5 million in 2050.1,2 In response to this alarming projection, the Lancet Commission – a panel of global clinical and public health experts – was established to tackle this issue.
Journal of Hepatology published a clinical update in Research Highlights on 02 Feb 2026.
The item focuses on Reversing the global burden of hepatocellular carcinoma.
Review the original article for the full source wording and details.